GenoFocus Inc (187420) - Net Assets
Based on the latest financial reports, GenoFocus Inc (187420) has net assets worth ₩54.75 Billion KRW (≈ $37.10 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩135.83 Billion ≈ $92.05 Million USD) and total liabilities (₩81.08 Billion ≈ $54.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GenoFocus Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩54.75 Billion |
| % of Total Assets | 40.31% |
| Annual Growth Rate | 17.08% |
| 5-Year Change | 55.19% |
| 10-Year Change | -12.43% |
| Growth Volatility | 75.39 |
GenoFocus Inc - Net Assets Trend (2014–2025)
This chart illustrates how GenoFocus Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of GenoFocus Inc for the complete picture of this company's asset base.
Annual Net Assets for GenoFocus Inc (2014–2025)
The table below shows the annual net assets of GenoFocus Inc from 2014 to 2025. For live valuation and market cap data, see GenoFocus Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩54.75 Billion ≈ $37.10 Million |
+130.33% |
| 2024-12-31 | ₩23.77 Billion ≈ $16.11 Million |
-9.83% |
| 2023-12-31 | ₩26.36 Billion ≈ $17.87 Million |
+10.34% |
| 2022-12-31 | ₩23.89 Billion ≈ $16.19 Million |
-32.28% |
| 2021-12-31 | ₩35.28 Billion ≈ $23.91 Million |
-11.29% |
| 2020-12-31 | ₩39.77 Billion ≈ $26.95 Million |
-23.70% |
| 2019-12-31 | ₩52.12 Billion ≈ $35.32 Million |
-13.44% |
| 2018-12-31 | ₩60.21 Billion ≈ $40.80 Million |
-6.24% |
| 2017-12-31 | ₩64.22 Billion ≈ $43.52 Million |
+2.72% |
| 2016-12-31 | ₩62.52 Billion ≈ $42.37 Million |
+109.88% |
| 2015-12-31 | ₩29.79 Billion ≈ $20.19 Million |
+208.31% |
| 2014-12-31 | ₩9.66 Billion ≈ $6.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GenoFocus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 610559523000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩4.00 Billion | 9.77% |
| Other Components | ₩36.92 Billion | 90.23% |
| Total Equity | ₩40.92 Billion | 100.00% |
GenoFocus Inc Competitors by Market Cap
The table below lists competitors of GenoFocus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
$58.07 Million |
|
ADVENICA AB
F:65R
|
$58.07 Million |
|
PW Consolidated Bhd
KLSE:7134
|
$58.09 Million |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
$58.10 Million |
|
Nimbus Group AB
ST:BOAT
|
$58.04 Million |
|
Selva Gida Sanayi AS
IS:SELVA
|
$58.02 Million |
|
Huvitz Co. Ltd
KQ:065510
|
$58.02 Million |
|
Arrienda Rental Properties SOCIMI SA
MC:YARP
|
$58.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenoFocus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,769,596,870 to 40,916,377,190, a change of 17,146,780,320 (72.1%).
- Net income of 22,591,370,470 contributed positively to equity growth.
- Other factors decreased equity by 5,444,590,150.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩22.59 Billion | +55.21% |
| Other Changes | ₩-5.44 Billion | -13.31% |
| Total Change | ₩- | 72.14% |
Book Value vs Market Value Analysis
This analysis compares GenoFocus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.93x to 2.09x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3160.30 | ₩2940.00 | x |
| 2017-12-31 | ₩3222.43 | ₩2940.00 | x |
| 2018-12-31 | ₩2761.55 | ₩2940.00 | x |
| 2019-12-31 | ₩2357.82 | ₩2940.00 | x |
| 2020-12-31 | ₩1775.39 | ₩2940.00 | x |
| 2021-12-31 | ₩1568.01 | ₩2940.00 | x |
| 2022-12-31 | ₩1060.71 | ₩2940.00 | x |
| 2023-12-31 | ₩968.28 | ₩2940.00 | x |
| 2024-12-31 | ₩815.82 | ₩2940.00 | x |
| 2025-12-31 | ₩1404.33 | ₩2940.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenoFocus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 55.21%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 52.09%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 3.32x
- Recent ROE (55.21%) is above the historical average (-10.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 22.58% | 35.48% | 0.36x | 1.75x | ₩1.22 Billion |
| 2015 | 4.07% | 18.24% | 0.22x | 1.02x | ₩-1.77 Billion |
| 2016 | 2.58% | 22.97% | 0.11x | 1.01x | ₩-4.64 Billion |
| 2017 | 2.20% | 12.26% | 0.16x | 1.09x | ₩-5.01 Billion |
| 2018 | -3.85% | -20.11% | 0.16x | 1.17x | ₩-8.34 Billion |
| 2019 | -11.05% | -38.53% | 0.17x | 1.73x | ₩-10.97 Billion |
| 2020 | -30.72% | -65.09% | 0.17x | 2.85x | ₩-16.19 Billion |
| 2021 | -19.32% | -26.35% | 0.22x | 3.36x | ₩-10.34 Billion |
| 2022 | -54.28% | -46.64% | 0.21x | 5.60x | ₩-15.36 Billion |
| 2023 | -13.39% | -10.92% | 0.28x | 4.44x | ₩-5.15 Billion |
| 2024 | -79.21% | -53.14% | 0.24x | 6.15x | ₩-21.21 Billion |
| 2025 | 55.21% | 52.09% | 0.32x | 3.32x | ₩18.50 Billion |
Industry Comparison
This section compares GenoFocus Inc's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $1,065,032,057,761
- Average return on equity (ROE) among peers: 4.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenoFocus Inc (187420) | ₩54.75 Billion | 22.58% | 1.48x | $58.05 Million |
| DL Holdings CO. LTD. (000210) | $3.21 Trillion | 15.72% | 3.33x | $1.01 Billion |
| DL Holdings Co Ltd Preferred (000215) | $5.15 Trillion | 5.16% | 1.41x | $34.58 Million |
| Norooholdings (000320) | $183.14 Billion | 6.11% | 0.87x | $153.49 Million |
| Noroo Holdings Co Ltd (000325) | $693.79 Billion | 3.67% | 0.71x | $5.20 Million |
| Samhwa Paint (000390) | $281.78 Billion | 0.27% | 0.98x | $158.92 Million |
| Kangnam Jevisco Co Ltd (000860) | $276.48 Billion | 8.94% | 0.31x | $148.36 Million |
| Paik Kwang Ind (001340) | $204.57 Billion | 3.85% | 1.06x | $219.31 Million |
| Bo Lak (002760) | $43.76 Billion | 2.53% | 0.22x | $46.56 Million |
| Songwon Industrial (004430) | $435.58 Billion | 7.98% | 1.05x | $257.79 Million |
| Cho Kwang Pain (004910) | $174.51 Billion | -13.98% | 0.99x | $33.78 Million |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more